These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 24737682

  • 1. Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.
    Colevas AD, Lira RR, Colevas EA, Lavori PW, Chan C, Shultz DB, Chang KW.
    Head Neck; 2015 Aug; 37(8):1102-7. PubMed ID: 24737682
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A new grading system for ototoxicity in adults.
    Theunissen EA, Dreschler WA, Latenstein MN, Rasch CR, van der Baan S, de Boer JP, Balm AJ, Zuur CL.
    Ann Otol Rhinol Laryngol; 2014 Oct; 123(10):711-8. PubMed ID: 24820112
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer.
    Zuur CL, Simis YJ, Verkaik RS, Schornagel JH, Balm AJ, Dreschler WA, Rasch CR.
    Radiother Oncol; 2008 Oct; 89(1):38-43. PubMed ID: 18706728
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of radiation and chemoradiation-induced sensorineural hearing loss in head and neck cancer patients.
    Mahdavi SR, Rezaeyan A, Nikoofar A, Bakhshandeh M, Farahani S, Cheraghi S.
    J Cancer Res Ther; 2020 Oct; 16(3):539-545. PubMed ID: 32719264
    [Abstract] [Full Text] [Related]

  • 17. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
    Caballero M, Mackers P, Reig O, Buxo E, Navarrete P, Blanch JL, Grau JJ.
    Oncology; 2017 Oct; 93(2):75-82. PubMed ID: 28511189
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Validation of Hearing Loss Prediction Tool for Cisplatin Chemotherapy and Radiation in Head and Neck Cancer Treatment.
    Deutsch BC, Collopy C, Kallogjeri D, Piccirillo JF.
    JAMA Otolaryngol Head Neck Surg; 2021 Feb 01; 147(2):182-189. PubMed ID: 33300954
    [Abstract] [Full Text] [Related]

  • 20. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.
    Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J.
    Pediatr Blood Cancer; 2012 Jul 15; 59(1):144-8. PubMed ID: 22431292
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.